Search Results

22 posts

Cochlear victorious but bruised in fight with ACCC over Danish implant tech

The ACCC has told Cochlear it won't oppose it's purchase of a Danish hearing aid competitor's…

Cochlear upgrades FY24 earnings guidance as shares surge 5pc

Cochlear (ASX:COH) is upgrading its earnings guidance following a better-than-expected growth of its ear implant for…

Cochlear (ASX:COH) notes 4pc decrease in sales revenue across H1 FY21

Cochlear (ASX:COH) experienced a four per cent decrease in sales revenue for H1 FY21 of $742.8…

Cochlear (ASX:COH) suffers $238.3M net loss in FY20

Despite a strong start to the 2020 financial year, Cochlear (ASX:COH) reported a net loss of…

Cochlear (ASX:COH) confirms significant impacts from COVID-19

Hearing technology company Cochlear (ASX:COH) has confirmed a significant decline in surgeries across the U.S. and…

Cochlear (ASX:COH) opens $50M share purchase plan

Cochlear (ASX:COH) has opened its share purchase plan (SPP) and is hoping to raise $50 million…

Cochlear (ASX:COH) raises $850M to combat “significant negative disruption” from COVID-19

Cochlear (ASX:COH) will raise $850 million after expecting a "significant negative impact" on business from COVID-19.

Cochlear (ASX:COH) loses appeal in $439M U.S. legal scuffle

Australian hearing aid creator Cochlear (ASX:COH) has lost its appeal to a U.S. District Court to…

Cochlear (ASX:COH) slashes earnings guidance entirely as Covid-19 spreads

Meditech giant Cochlear (ASX:COH) is the latest in a string of companies to withdraw its earnings…

Cochlear (ASX:COH) hears an earnings reduction after coronavirus sweep

Due to the coronavirus outbreak, Cochlear (ASX:COH) has reduced its 2020 financial year earnings guidance from…

Cochlear’s profits boom 13 per cent despite drop in implant sales

Hearing aid producer Cochlear has seen its profits rise 13 per cent during the 2019 financial…

Cochlear jumps 4.8 per cent on new implant device

Cochlear Limited has announced the launch of the Nucleus Profile Plus Series Cochlear implant.
The Market Online Video

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Recce Pharmaceuticals (ASX:RCE) has confirmed its completion of the latest study using its R327 anti-infective as…

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…

Imugene reaches next cohorts in monotherapy and combination study for cancer-killing virus, Vaxinia

Imugene (ASX:IMU) has reached the next cohorts in the IV arm of its monotherapy dose escalation…

Recce Pharmaceuticals (ASX:RCE) completes cohort dosing in UTI rapid infusion trial

Recce Pharmaceuticals (ASX:RCE) has completed dosing male and female subjects in its phase I/II UTI-urosepsis clinical…

Riding the wave of wellness: The growing non-alcoholic, herbal, and alternative beverage market

In recent years, there has been a notable shift in consumer preferences towards alternative beverages that…

Imugene (ASX:IMU) clears cohort one in VAXINIA MAST trial

Imugene (ASX:IMU) has announced the clearance of the first cohort in its phase one MAST trial,…

PharmAust (ASX:PAA) escalates dosage of third patient cohort in MND/ALS trial

PharmAust (ASX:PAA) has announced that all 12 patients in cohort three have received an initial escalated…

Imugene (ASX:IMU) advances VAXINIA MAST trial to next cohort

Imugene's (ASX:IMU) phase one metastatic advanced solid tumours trial evaluating its novel cancer-killing drug, VAXINIA, has…